Please wait while we open this resource.
K
Clinical reviews
MYELODYSPLASTIC SYNDROMES: 2023 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT
University of Texas MD Anderson Cancer Center
PDF202319 pages3.0 MB
Myelodysplastic syndromes (MDS) are characterized by peripheral blood cytopenias and an increased risk of transformation to acute myelogenous leukemia (AML). The diagnosis is based on morphological evidence of dysplasia from bone marrow aspirates and biopsies, complemented by additional studies. The document outlines the Revised International Prognostic Scoring System (IPSS-R) and the new IPSS-M classification, which incorporates genomic data for prognosis. It also details various therapeutic approaches based on risk stratification and patient profiles.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Myeloproliferative Neoplasms
Same clinical topic · Hematology
MASTOCYTOSIS
Same clinical topic · Hematology
PERIPHERAL T-CELL LYMPHOMAS
Same clinical topic · Hematology
COMPARISON OF THE INTERNATIONAL CONSENSUS AND 5TH WHO EDITION CLASSIFICATIONS OF ADULT MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Same clinical topic · Hematology
VEXAS SYNDROME: A COMPREHENSIVE REVIEW OF PATHOGENESIS, CLINICAL SPECTRUM, AND THERAPEUTIC STRATEGIES
Same clinical topic · Hematology
IRON DEFICIENCY
Same clinical topic · Hematology
MULTIPLE MYELOMA: 2026 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION AND MANAGEMENT
Same clinical topic · Hematology
ANTIDOTES FOR ANTICOAGULATION REVERSAL
Same clinical topic · Hematology
POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND ANTHYMOCTE GLOBULIN IN 8/10 HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATION
Same clinical topic · Hematology